---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-019133"
form_type: "8-K"
ticker: "TNGX"
cik: "0001819133"
company_name: "Tango Therapeutics, Inc."
filed_at: "2023-05-09T23:59:59+00:00"
generated_at: "2026-06-15T09:47:08.032835+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Tango Therapeutics Q1 net loss $0.32/sh; cash $334M funds pipeline into 2026

## Summary
- Q1 net loss $28.0M ($0.32 per share) vs $25.2M ($0.29) in prior year; revenue flat at $5.8M.
- Cash and equivalents $333.6M; expects to fund operations into 2026.
- TNG908 shows proof-of-mechanism with selective PRMT5 inhibition in MTAP-deleted tumors; no DLTs or grade >2 AEs.
- FDA cleared IND for TNG260 (CoREST inhibitor) and granted Fast Track designation for STK11-mutant NSCLC; phase 1/2 to start 2H 2023.
- Appointed Adam Crystal, M.D., Ph.D., as President of R&D in February 2023.

## SEC filing metadata
- accession: 0000950170-23-019133
- form_type: 8-K
- ticker: TNGX
- cik: 0001819133
- company_name: Tango Therapeutics, Inc.
- filed_at: 2023-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819133/000095017023019133/0000950170-23-019133-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819133/000095017023019133/tngx-20220810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-019133
- JSON: https://secwatch.observer/filing/0000950170-23-019133.json
- Plain text: https://secwatch.observer/filing/0000950170-23-019133.txt

## Key facts
- Earnings Releases
  Tango Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2023.
  - Period: the first quarter ended March 31, 2023
  - Result: reported results
  source text: Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the first quarter ended March 31, 2023, and provided business highlights.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1819133/000095017023019133/0000950170-23-019133-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.